恩福妥单抗和帕博利珠单抗联合治疗在尿路上皮癌中的相关变革：还有什么遗留问题？
Enfortumab vedotin and pembrolizumab combination as a relevant game changer in urothelial carcinoma: What is left behind?
机构信息
Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Hospital del Mar Research Institute Lab (IMIM), Barcelona, Spain.
National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.
出版信息
Med. 2024 Jun 14;5(6):490-492. doi: 10.1016/j.medj.2024.04.006.
The EV-302 study marks a pivotal leap in the management of advanced urothelial carcinoma, setting a new benchmark for frontline therapy. Enfortumab vedotin plus pembrolizumab is the first combination therapy that has ever outperformed standard chemotherapy. The degree of benefit and the reported safety profile should make this combination a first-choice option for most patients with advanced-stage urothelial carcinoma.
EV-302 研究标志着晚期尿路上皮癌治疗的重大飞跃，为一线治疗树立了新的标杆。恩沃利单抗联合帕博利珠单抗是首个疗效优于标准化疗的联合治疗方案。其获益程度和安全性特征应使该联合方案成为大多数晚期尿路上皮癌患者的首选方案。
Zotero 插件